

KOS Diagnostic Lab

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mrs. KULPREET BHATIA

AGE/ GENDER : 48 YRS/FEMALE **PATIENT ID** : 1680634

COLLECTED BY : REG. NO./LAB NO. : 012411230059

 REFERRED BY
 : 23/Nov/2024 06:44 PM

 BARCODE NO.
 : 01521333
 COLLECTION DATE
 : 23/Nov/2024 06:45 PM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 23/Nov/2024 06:49 PM

CLIENT ADDRESS: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

SPECIAL INVESTIGATIONS

IMMATURE PLATELET FRACTION (IPF) WITH OTHER PREDICTIVE MARKERS

IMMATURE PLATELET FRACTION (IPF) AND OTHER PREDICTIVE MARKERS

IMMATURE PLATELET FRACTION (IPF) by FLOURESCENT FLOW CYTOMETRY	24.8 ^H	%	1.0 - 9.0
PLATELET COUNT (PLT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	20000 ^L	/cmm	150000 - 450000
PLATELET LARGE CELL COUNT (P-LCC) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	8000 ^L	/cmm	30000 - 90000
MEAN PLATELET VOLUME (MPV) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	11	fL	6.50 - 12.0
PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	0.02 ^L	%	0.10 - 0.36
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	42.9	%	11.0 - 45.0
PLATELET DISTRIBUTION WIDTH (PDW) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE & MICROSCOPY	16	%	15.0 - 17.0



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)





KOS Diagnostic Lab

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. KULPREET BHATIA

AGE/ GENDER : 48 YRS/FEMALE **PATIENT ID** : 1680634

COLLECTED BY REG. NO./LAB NO. :012411230059

REFERRED BY **REGISTRATION DATE** : 23/Nov/2024 06:44 PM BARCODE NO. :01521333 **COLLECTION DATE** : 23/Nov/2024 06:45PM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 23/Nov/2024 06:49PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit **Biological Reference interval**

INTERPRETATION:

- 1. The immature platelet fraction (%IPF) is a modern parameter that measures young and thereby reticulated platelets in peripheral blood.

 2. The reference range is approximately 1 to 5% of the total platelet count.
- 3. IPF levels rise as bone marrow production of platelets increases
- 4. There is a high clinical utility of the % IPF in the laboratory diagnosis and treatment of thrombocytopenia due to the ability to relate raised % IPF levels with increased peripheral platelet destruction.

 BENEFITS OF IMMATURE PLATELET FRACTION (IPF):

- 1. It is particularly useful for supporting the diagnosis of autoimmune thrombocytopenic purpura, thrombotic thrombocytopenic purpura and for distinguishing these from bone marrow suppression or failure, dengue. In the case of the latter, the %IPF value would be low.

 2. A single value IPF more than 10% was indicative of platelet recovery within 24-48 Hours. A positive correlation was observed among immature platelet fraction (IPF) level and the recovery of platelets in those particular was read and the recovery of platelets in those particular was read and the recovery of platelets in those particular was read and the recovery of platelets in those particular was read and the recovery of platelets.
- The IPF count supports clinicians in differentiating between consumptive versus productive reasons for thrombocytopenia and helps avoid a bone marrow biopsy with obvious benefits for the patient

IPF - A UNIQUE PARAMETER FOR FOLLOWING REASONS:

- 1. Automated, easy to perform, standardized results
- 2. Inexpensive3. Results available 24/7 for rapid response to clinicians
- 4. Could reduce time and cost of diagnosis of thrombocytopenia by the physician5. May provide useful information for tailoring treatment regimens by allowing clinicians to link treatment options to mechanisms of low cell
- 6. Provides the clinician with valuable information in the assessment of the mechanism of newly discovered thrombocytopenias and secondary thrombocytopenias (HIV, Hepatitis C, drugs etc.)

End Of Report ***



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

